


A vertical bar on the left side of the slide, transitioning from red at the top to dark blue at the bottom.

# Biomolecular Applications of LC/MS

LC/MS for biomolecule applications:  
“leveraged synergy across many technology platforms”



Copyright © 1997 United Feature Syndicate, Inc.  
Redistribution in whole or in part prohibited

# Overview

- Biomolecule LC/MS basics
  - mass spectrometry (MS) instrumentation
    - triple quads, ion traps, MS, MS/MS, MS<sup>n</sup>
  - electrospray ionization (ESI)
    - mass range, multiple charging
  - Peptide sequencing
    - database searching for protein i.d.
    - De novo sequencing (*a more advanced topic*)
- Methods and Applications
  - Case studies
    - Protein i.d. from gel-separated proteins
    - Applications in biopharmaceuticals
  - Automation strategies
    - Sample cleanup
    - On-line digestion
    - On-line interaction screening
    - Data-handling strategies

# Information Obtainable via ESI/LC/MS<sup>n</sup>


- ▶ **Molecular Weight**
  - confirmation of sequence
  - screening for post-translational or other covalent modifications
  - heterogeneity/impurity profiling
- ▶ **Structural Information (via MS/MS or MS<sup>n</sup>)**
  - sequence confirmation
  - protein identification from database searching of fragment ions
  - disulfide bond mapping
  - determination of sites of modification or mutation
- ▶ **Binding/Interaction**
  - on-line affinity selection or affinity chromatography

## Challenges/limitations of LC/MS for Biomolecular Analysis

- ESI/MS of intact proteins can be difficult if protein is too heterogeneous
- most protein i.d. requires enzyme digestion first
- detergents interfere with LC/MS analysis and must be removed which is non-trivial
- low tolerance of ESI to salt and 100% aqueous solns makes analysis of proteins in their native state difficult
- Information and data overload!

# LC/Electrospray Ionization/MS


Electrospray ionization (ESI): separation of ions from bulk solution so that they may be analyzed in the gas phase (mass spectrometry)



# Schematic Diagram of a Triple Quadrupole Mass Spectrometer

## A "tandem-in-space" mass spectrometer

different stages of mass analysis performed in discrete regions (quads 1 or 3)




strengths: great general purpose system MS, MS/MS, neutral loss and parent scans useful for mixture screening, **best instrument for intact protein analysis**, no low mass cut-off in MS/MS mode like the ion trap, data-dependent scanning  
limitations: less sensitive than ion trap in the full scan MS/MS mode

# Determination of Protein MWs using Deconvolution


HCMV Protease (MW 28049)

Multiply-charge ion envelope


Raw ESI mass spectrum




deconvolution step 1




deconvolution step 2




deconvolution step 3




# Importance of protein sample cleanup by LC/MS: analysis of 80 kDa human transferrin



# Proteins require enzymatic cleavage before sequencing can occur by MS



## Fragmentation in MS/MS produces sequence-specific fragment ions



- Use database search routines to identify or profile **known** proteins

- *De novo* sequencing requires **interpretation** of spectra either manually or by computer algorithm

- peptides fragment along the amide backbone to produce sequence specific fragment ions

- different patterns of sequence ions are produced from the different masses of the side chain groups

- ions containing the N-terminus are typically of type 'a' or 'b'


- ions containing the C-terminus are known as 'y' ions

- tryptic peptides predominantly produce ions of type 'y' due to the presence of Arg or Lys at the C-terminus

# Schematic Diagram of the Finnigan LCQ Ion Trap MS

## A "tandem-in-time" mass spectrometer

different stages of mass analysis performed in the same physical space at discrete points in time




strengths: compact, MS<sup>n</sup>, excellent full scan MS/MS sensitivity, excellent data dependency, the ultimate peptide mapping system

limitations: limited storage of ions, 1/3 of low mass range lost in MS/MS modes


# Ion trap scanning terminology for bio-LC/MS applications

- Data-dependent scanning
  - Having the instrument switch scan modes once a signal threshold has been exceeded
  - A key advantage of the Finnigan ion trap systems
  - Maximizes information content in a single LC/MS<sup>n</sup> run
- LCQ “Triple Play” - a data-dependent scan type
  - Full scan (find signals for MS/MS)
  - Zoom scan (determine charge state to calculate MW)
  - Full MS/MS scan (used to delineate peptide sequence, via SEQUEST database search or *de novo* methods)
- Dynamic Exclusion - enhanced data-dependency
  - Ion traps yield excellent MS/MS spectra with a single scan
  - Therefore, why waste instrument time collecting additional spectra on the same signals?
  - Dynamic exclusion - ignore masses (for a period) whose MS/MS spectra have already been collected
  - Allows “drilling down” further into the data
  - Applications: complex mixtures of co-eluting peaks, e.g., complex peptide maps


# Example of LCQ "triple play" data-dependent analysis



# The "Dynamic Exclusion" Experiment



# SEQUEST database cross-correlation for rapid protein identification




## Database Search Results

Database:genpept.fsa  
File:ERFHASVR.dat

Mass:1001.00 Charge:2  
Scan:Off-line centroid

No.	Rank	Corr.	Protein Information	Mult	Ions	NCBI#	Subsequence
1)	1	1.000	(M88011) glucokinase [Homo sapiens]	+	3	179427	ERFHASVR
2)	2	0.976	(U61948) similar to the non-receptor class of pr		10/12	1397280	RKRKEKR
3)	2	0.976	(U51032) D9651.5 gene product [Saccharomyces cer	+	1	1230662	RKRQEKR
4)	3	0.964	(U08315) calnexin homolog [Arabidopsis thaliana]		10/12	473878	RKRQTRR
5)	4	0.955	(X78823) phenoxybenzoate dioxygenase [Pseudomona		12/14	473250	GVIYHAWR
6)	5	0.940	(Z68001) C11G10.2 [Caenorhabditis elegans]		10/12	1070045	RERQKER
7)	5	0.940	(U09820) helicase II [Homo sapiens]		10/12	606833	RERKQER
8)	6	0.938	(X07384) GLI protein (AA 1-1106) [Homo sapiens]		14/18	31768	ASDPAQAADR
9)	7	0.932	(U19151) putative reverse transcriptase; contain		10/12	624681	RKREEQR
10)	7	0.932	(Z46259) NO388 gene product [Saccharomyces cerev	+	1	633674	RKREEKR

# SEQUEST can be run directly from a browser



# SEQUEST Summary screen

Sequest Summary - Microsoft Internet Explorer

Address: http://www.enovatia.com:81/cgi-bin/runsummary.pl?directory=mhailjay2&sort=consensus

## Sequest Summary

[Setup](#) [CreateDTA](#) [FuDTA](#) [FunSequest](#) [Status](#) [Summary](#) [Utilities](#) [Home](#)


**Sample:** Hail, M. (JAY2) JAY2 meh **Db:** owl (01/10/2000) and contaminants\_and\_integrin\_nr **Inspector:** Vi  
**Datafiles:** jay201 (06/02/2000-06/05/2000) **Dir:** mhailjay2 **Enz:** Trypsin  
**Intensity:**  Full  Zoom  MS2 **Diff Mods:** 57 C 16 Mdiff\_search\_options = N  
**Consensus** **Chron** **Max rank:** 3 **Max list:** 5 **Controls:** **Show** **DTA VCR**

#	TIC	File	z	dM	MH+	%corr	dCn	Sp	RSp	Ions	Ref	( )	Sequence
<b>Pull to Top</b>													
<b>A</b> owl P05556 ITB1_HUMAN 98 15 4.3e7 70% (9,1,0,1,0,0) (2 3 6 7 8 9 13 14 16 18 21 24 25 31, 27, x, 20, x, x)													
*FIBRONECTIN RECEPTOR BETA SUBUNIT PRECURSOR (INTEGRIN BETA-1)													
8	8.9e5	0438	3	-1.1	1846.1	3.82	0.25	1164	1	26/60	owl p05556 itb1	(R)	DKLPQPVQDPVSHCK
6	8.0e5	0432	2	0.1	1536.4	3.60	0.30	1298	1	16/20	owl p53712 itb1	+6	(K) FCECDNFNCDR
25	1.2e7	0575	2	0.3	1091.3	3.59	0.33	1038	1	15/18	owl p53712 itb1	+2	(K) GEVFNELVVK
31	2.0e6	0690	2	-0.4	1267.0	3.29	0.39	1353	1	17/20	owl p53712 itb1	+4	(K) SLGTDLMNEMR
18	1.5e6	0531	2	0.2	1282.4	3.26	0.35	1309	1	17/20	owl p53712 itb1	+4	(K) SLGTDLMNEM*R
16	5.1e6	0511	2	-0.7	1223.3	3.22	0.36	550	1	12/18	owl p12607 itb0	+10	(K) WDTGENPIYK
3	2.2e6	0420	2	0.2	1298.4	3.01	0.33	1537	1	17/20	owl p53712 itb1	+4	(K) SLGTDLMNEM*R
14	5.5e6	0482	2	-0.5	1097.1	2.91	0.31	768	1	14/18	owl p05556 itb1		(K) LSEGVTISYK
9	3.5e6	0450	2	0.3	1107.3	2.58	0.15	215	76	12/18	owl p53712 itb1	+2	(R) SGEPQTFILK
7	1.5e6	0435	2	0.3	1324.4	2.36	0.13	461	1	14/22	owl p12607 itb0	+8	(K) TVM*PYISTTPAK
21	9.2e5	0540	2	0.3	1308.3	2.24	0.05	364	4	14/22	owl p12607 itb0	+8	(K) TVMPYISTTPAK
27	3.1e6	0627	1	0.1	983.4	2.16	0.14	280	26	9/16	owl p18563 itb6	+2	(R) LGFGSFVEK
13	1.5e6	0479	1	0.1	1096.5	1.99	0.14	255	10	9/18	owl p05556 itb1		(K) LSEGVTISYK
2	8.3e5	0393	2	-1.7	1337.2	1.85	0.00	370	1	14/24	owl p05556 itb1		(R) SNGLIC*GGNGVC*K
24	2.3e6	0572	1	0.3	1091.3	1.80	0.04	279	33	9/18	owl p53712 itb1	+2	(K) GEVFNELVVK
<b>F</b> owl U36884 HIV1U36884 16 2 5.5e5 1% (0,2,0,0,0,0) (x, 19 32, x, x, x, x)													
*HIV1U36884 NID: g1079641 - Human immunodeficiency virus type 1.													
32	3.3e5	0699	3	-0.2	2195.5	2.44	0.04	271	93	21/68	owl ab018306 ab		(R) EIFLFDLLVVKIFQKK
19	2.2e5	0534	2	0.4	1629.5	1.58	0.03	115	118	9/26	owl u76714 rru7		(R) LADMNATIRRIDQL
<b>G</b> owl AF026492 AF026492 14 2 6.3e5 1% (0,1,1,0,0,0) (x, 29, 5, x, x, x)													
*AF026492 NID: a2564720 - yellow fever mosquito.													

Done Internet

15 "hits" from the same protein

# A real bio-LC/MS case study: anomalous heterogeneity found in early antibody production



Light chain  
Heavy chain  
carbohydrate

## Backdrop

- Antibody (148 kDa) being considered for therapeutic use
- Early cell line growth and “master well” selection
- Early development, pre-IND phase


## What happened?

- Routine MW profiling of the intact protein by ESI/MS revealed a potential purity issue
- Used a combination of intact protein MS (triple quad) and peptide mapping LC/MS/MS (ion trap) to solve the problem
- Confirmed by consulting biology collaborators and considering biologically feasible options


# Analysis of intact antibody via ESI/MS

TSQ 7000 w/API-2



anti-cd40  
igg4d 1 (0.060) Sb (7,20.00)



anti-cd40  
igg4d 1 (0.060) Tr (1999:3599,1.00,Mid); Sb (7,20.00)



# Investigation of IgG micro-heterogeneity by ESI/MS




# Heterogeneity follows F(ab')<sub>2</sub> fragment

mass difference appears to be ~100 Da

anti-cd40


cd40fab1 1 (0.021) Sb (7,20.00)



ESI mass spectrum of F(ab')<sub>2</sub> fragment

anti-cd40

cd40fab1 1 (0.021) Tr (1299:2399,1.00,Mid); Sb (7,20.00)




# LC/MS/MS peptide mapping of LysC digest of IgG reveals anomaly in "bad" sample lot

C:\Xcalibur\data\igg4lysca

09/30/1999 10:49:24 AM


IgG Lys-C digest 2.5 pm/uL x 20ul TFA mobile phase

RT: 0.00 - 34.98




# Unknown peptide is not present in “good” lots

RT: 0.00 - 35.04



RT: 0.00 - 35.02




We used this simple mass chromatogram approach to screen several lots for the unknown peptide. We were able to isolate the “problem” to a single master well.

# MS/MS spectrum confirming identity of unknown peptide

Mutation at position 138 on heavy chain confirmed to be Arg->Gly

Seq	#	b	y	#
G	1	58.0	2593.3	26
P	2	155.1	2536.3	25
S	3	242.1	2439.2	24
V	4	341.2	2352.2	23
F	5	488.3	2253.1	22
P	6	585.3	2106.0	21
L	7	698.4	2009.0	20
A	8	769.4	1895.9	19
P	9	866.5	1824.9	18
C	10	1026.5	1727.8	17
S	11	1113.5	1567.8	16
G	12	1170.6	1480.7	15
S	13	1257.6	1423.7	14
T	14	1358.6	1336.7	13
S	15	1445.7	1235.6	12
E	16	1574.7	1148.6	11
S	17	1661.8	1019.6	10
T	18	1762.8	932.5	9
A	19	1833.8	831.5	8
A	20	1904.9	760.4	7
L	21	2018.0	689.4	6
G	22	2075.0	576.3	5
C	23	2235.0	519.3	4
L	24	2348.1	359.3	3
V	25	2447.2	246.2	2
K	26	2575.3	147.1	1



# How did we figure it out?

- We collected MS of the intact antibody and saw some “odd” looking peaks, lower by ~100 Da.
- We looked at the F(ab')<sub>2</sub> fragment, the odd looking peaks were present, therefore modification must be on this portion of the molecule - I.e., not on the Fc portion on the heavy chain
- Reduced/alkylated, digested with LysC (and trypsin)
- Performed data-dependent LC/MS/MS expts. on ion trap
- Used SEQUEST to identify all of the known peptides
- Looked for signals that did not correlate
- Found a peptide 99 Da lower in mass which eluted near a known peptide, inspected MS/MS spectrum
- Considered AA modifications that would give this result
- Arg -> Gly substitution made the most sense
  - MS/MS spectrum verification
  - Peptide is not cleaved in the tryptic digest, suggests that Arg has been converted to something else
  - From the genetic code, modification of a single base in the codon could cause this to happen (later isolated to a single master well)

# Only 2 possibilities for -99 Da mass shift

<http://prowl.rockefeller.edu/aainfo/mutation.html>

Mutation Mass Shifts  
Masses changes between various amino acids)

1. Residues DOWN the left indicate the EXPECTED residues.
2. Residues ACROSS the top indicate the MUTANT residues.

		Leu/Ile							Gln/Lys										
	Gly	Ala	Ser	Pro	Val	Thr	Cys	Ile	Asn	Asp	Lys	Glu	Met	His	Phe	Arg	Tyr	Trp	
	57	71	87	97	99	101	103	113	114	115	128	129	131	137	147	156	163	186	
Gly	57		14	30	40	42	44	46	56	57	58	71	72	74	80	90	99	106	129
Ala	71	-14		16	26	28	30	32	42	43	44	57	58	60	66	76	85	92	115
Ser	87	-30	-16		10	12	14	16	26	27	28	41	42	44	50	60	69	76	99
Pro	97	-40	-26	-10		2	4	6	16	17	18	31	32	34	40	50	59	66	89
Val	99	-42	-28	-12	-2		2	4	14	15	16	29	30	32	38	48	57	64	87
Thr	101	-44	-30	-14	-4	-2		2	12	13	14	27	28	30	36	46	55	62	85
Cys	103	-46	-32	-16	-6	-4	-2		10	11	12	25	26	28	34	44	53	60	83
Leu/Ile	113	-56	-42	-26	-16	-14	-12	-10		1	2	15	16	18	24	34	43	50	73
Asn	114	-57	-43	-27	-17	-15	-13	-11	-1		1	14	15	17	23	33	42	49	72
Asp	115	-58	-44	-28	-18	-16	-14	-12	-2	-1		13	14	16	22	32	41	48	71
Gln/Lys	128	-71	-57	-41	-31	-29	-27	-25	-15	-14	-13		1	3	9	19	28	35	58
Glu	129	-72	-58	-42	-32	-30	-28	-26	-16	-15	-14	-1		2	8	18	27	34	57
Met	131	-74	-60	-44	-34	-32	-30	-28	-18	-17	-16	-3	-2		6	16	25	32	55
His	137	-80	-66	-50	-40	-38	-36	-34	-24	-23	-22	-9	-8	-6		10	19	26	49
Phe	147	-90	-76	-60	-50	-48	-46	-44	-34	-33	-32	-19	-18	-16	-10		9	16	39
Arg	156	-99	-85	-69	-59	-57	-55	-53	-43	-42	-41	-28	-27	-25	-19	-9		7	30
Tyr	163	-106	-92	-76	-66	-64	-62	-60	-50	-49	-48	-35	-34	-32	-26	-16	-7		23
Trp	186	-129	-115	-99	-89	-87	-85	-83	-73	-72	-71	-58	-57	-55	-49	-39	-30	-23	


Arg -> Gly  
Trp -> Ser

kclausner@rafael.ucsf.edu 5/1/95

# A real bio-LC/MS case study: identification of immunoprecipitated protein separated by SDS-PAGE

Photo of 1-D SDS-PAGE of immunoprecipitate from human fibrosarcoma cell lysate  
~200 fmoles **TOTAL** loaded

① 1-D SDS-PAGE (7.5% acrylamide gel)




Coomassie blue stained gel

# Protein i.d. case study

## Experimental Approach



- Excise protein from gel
- Perform in-gel digest
- Inject onto nano-LC (use nano-scale trapping column to preconcentrate sample) on-line with ion trap MS
- Perform data-dependent “triple-play” scanning: MS scan, hi-res zoom scan, MS/MS scan
- Analyze results using TurboSEQUENT protein database cross-correlation program

# Photo of Experimental nano-LC/MS/MS system




# Data-dependent LC/MS/MS analysis of in-gel digest sample

RT: 0.00 - 22.00




# Example of triple-play data from in-gel digest sample


jay201 #480 RT: 13.93 AV: 1 NL: 1.68E6  
T: + c NSI Full ms [500.00-2000.00]



jay201 #481 RT: 13.96 AV: 1 SM: 15G NL: 6.99E4  
T: + d 2 ms [545.00-555.00]



Seq #	b	y	(+1)
L 1	114.1	1096.6	10
S 2	201.1	983.5	9
E 3	330.2	896.5	8
G 4	387.2	767.4	7
V 5	486.3	710.4	6
T 6	587.3	611.3	5
I 7	700.4	510.3	4
S 8	787.4	397.2	3
Y 9	950.5	310.2	2
K 10	1078.6	147.1	1



MS/MS spectrum of m/z 549

# SEQUEST summary from LC/MS/MS analysis of in-gel digest sample

File Edit View Fav  
Back Forward

Address [http://localhost/cgi-bin/runsummary.pl?directory=mhailjay2\\_itb1&sort=consensus](http://localhost/cgi-bin/runsummary.pl?directory=mhailjay2_itb1&sort=consensus) Go Links >>

## Sequest Summary

[Setup](#) [CreateDTA](#) [VuDTA](#) [RunSequest](#) [Status](#) [Summary](#) [Utilities](#) [Home](#)

Sample: Hail, M. (JAY2\_ITB1) JAY2 meh      Db: [nr](#) (05/12/2000)      Inspector:      View Info      Mass: Mono  
 Datafiles: [jay201](#) (06/03/2000-06/03/2000)      Dir: [mhailjay2\\_itb1](#)      Enz: Trypsin      Tot: 13|13|3.1e7  
 Intensity:  Full  Zoom  MS2      Diff Mods: 57 C 16 M X

Consensus Chron Max rank:  Max list:  Controls:

#	TIC	File	z	dM	MH+	%corr	dCn	Sp	RSp	Ions	Ref	()	Sequence	Pull to Top
---	-----	------	---	----	-----	-------	-----	----	-----	------	-----	----	----------	-------------

<p><b>A</b> <a href="#">gi 4504767 ref NP_002202.1</a> 88 13 3.1e7 100% {8,1,0,0,0,0} (1 2 3 4 5 6 7 8 9 10 11 13, 12, x, x, x, x)                      *integrin, beta 1 (fibronectin receptor, betapolypeptide, antigen CD29 includes MDF2, MSK12)gi 124963 sp P05556 ITB1_HUMAN FIBRONECTIN RECEPTOR BETA SUBUNIT PRECURSOR (INTEGRIN BETA-1) (CD29)(INTEGRIN VLA-4 BETA SUBUNIT)gi 87429 pir B27079 fibronectin receptor beta chain precursor - humangi 31442</p>														
13	2.0e6	<a href="#">0690</a>	2	-0.4	1267.0	3.92	0.43	1353	1	17/20	<a href="#">gi 4504767</a>	+5	<a href="#">(K) SLGTDLMNEMR</a>	
4	8.9e5	<a href="#">0438</a>	3	-1.2	1846.1	3.84	0.26	1453	1	29/60	<a href="#">gi 4504767</a>		<a href="#">(R) DKLPQPVQDPVSHC*K</a>	
2	8.0e5	<a href="#">0432</a>	2	0.1	1536.4	3.26	0.32	1042	1	15/20	<a href="#">gi 4504767</a>	+7	<a href="#">(K) FC*EC*DNFNC*DR</a>	
8	5.1e6	<a href="#">0511</a>	2	-0.7	1223.3	3.23	0.41	1131	1	16/18	<a href="#">gi 4504767</a>	+14	<a href="#">(K) WDTGENPIYK</a>	
7	5.5e6	<a href="#">0482</a>	2	-0.5	1097.1	3.08	0.36	1202	1	16/18	<a href="#">gi 4504767</a>		<a href="#">(K) LSEGVTISYK</a>	
9	1.5e6	<a href="#">0531</a>	2	0.2	1282.4	3.03	0.37	1134	1	16/20	<a href="#">gi 4504767</a>	+5	<a href="#">(K) SLGTDLMNEM#R</a>	
1	2.2e6	<a href="#">0420</a>	2	0.2	1298.4	2.73	0.22	1201	1	16/20	<a href="#">gi 4504767</a>	+5	<a href="#">(K) SLGTDLM#NEM#R</a>	
3	1.5e6	<a href="#">0435</a>	2	0.3	1324.4	2.66	0.20	405	2	14/22	<a href="#">gi 4504767</a>	+10	<a href="#">(K) TVM#PYISTTPAK</a>	
5	3.5e6	<a href="#">0450</a>	2	0.3	1107.3	2.65	0.24	470	1	14/18	<a href="#">gi 4504767</a>	+2	<a href="#">(R) SGEPQTFLLK</a>	
10	9.2e5	<a href="#">0540</a>	2	0.3	1308.3	2.35	0.21	507	1	15/22	<a href="#">gi 4504767</a>	+10	<a href="#">(K) TVMPYISTTPAK</a>	
11	2.3e6	<a href="#">0572</a>	1	0.3	1091.3	2.09	0.17	348	11	10/18	<a href="#">gi 4504767</a>	+2	<a href="#">(K) GEVFNELVGK</a>	
12	3.1e6	<a href="#">0627</a>	1	0.1	983.4	2.04	0.12	557	1	12/16	<a href="#">gi 4504775</a>	+3	<a href="#">(R) LGFGSFVEK</a>	
6	1.5e6	<a href="#">0479</a>	1	0.1	1096.5	2.01	0.19	322	5	10/18	<a href="#">gi 4504767</a>		<a href="#">(K) LSEGVTISYK</a>	

Confirmed hits for integrin beta-1

<p><b>A</b> <a href="#">gi 4504767 ref NP_002202.1</a> 88 {8,1,0,0,0,0} (1 2 3 4 5 6 7 8 9 10 11 13, 12, x, x, x, x)                      *integrin, beta 1 (fibronectin receptor, betapolypeptide, antigen CD29 includes MDF2, MSK12)gi 124963 sp P05556 ITB1_HUMAN FIBRONECTIN RECEPTOR BETA SUBUNIT PRECURSOR (INTEGRIN BETA-1) (CD29)(INTEGRIN VLA-4 BETA SUBUNIT)gi 87429 pir B27079 fibronectin receptor beta chain precursor - humangi 31442</p>														
<p><b>B</b> <a href="#">gi 1708573 sp P53712 ITB1_BOVIN</a> 68 {6,1,0,0,0,0} (1 2 3 5 8 9 10 11 13, 12, x, x, x, x)</p>														
<p><b>C</b> <a href="#">gi 1708574 sp P53713 ITB1_FELCA</a> 58 {5,1,0,0,0,0} (2 3 5 8 10 11, 12, x, x, x, x)</p>														
<p><b>D</b> <a href="#">gi 124964 sp P09055 ITB1_MOUSE</a> 48 {4,1,0,0,0,0} (1 2 3 8 9 10 13, 12, x, x, x, x)  <a href="#">gi 1352494</a>, <a href="#">gi 72070</a>, <a href="#">gi 762977</a></p>														
<p><b>E</b> <a href="#">gi 124961 sp P12607 ITBO_XENLA</a> 28 {2,1,0,0,0,0} (3 8 10, 12, x, x, x, x)  <a href="#">gi 124962</a>, <a href="#">gi 124965</a></p>														

\*Database nr.fasta unavailable for sequence descriptions.

# Sequence coverage map of integrin beta-1 from LC/MS/MS analysis

Address <http://localhost/cgi-bin/flicka.pl?Db=d:/Xcalibur/database/nr.fasta&MassType=1&Pep=SLGTDLMNEMR+GEVFNELVGK+TVMPYISTTPAK+FCECDNFNCDR+> Go Links >>

*Flicka*

[Setup](#) [Create DTA](#) [Yu DTA](#) [Run Sequest](#) [Status](#) [Summary](#) [Utilities](#) [Home](#)

Send to: [PEPCUT](#) [PEPSTAT](#) [BLAST](#) NCBI: [SEQUENCE](#) [ABSTRACT](#)

```
>gi|4504767|ref|NP_002202.1| integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes
MDF2, MSK12) [gi|124963|sp|P05556|ITB1_HUMAN FIBRONECTIN RECEPTOR BETA SUBUNIT PRECURSOR (INTEGRIN BETA-1) (CD29)
(INTEGRIN VLA-4 BETA SUBUNIT) [gi|87429|pir|B27079 fibronectin receptor beta chain precursor -
human [gi|31442|emb|CAA30790.1| (X07979) integrin beta 1 subunit precursor [Homo sapiens]
MNLQPIFWIG LISSVCCVFA QTDENRCLKA NAKSCGECIQ AGPNCGWCTN STFLQEGMPT SARCDLEAL KKGCPDDI
ENPRGSKDIK KNKNVTNRSK GTAELKLPED IHQIQPQLV LRLRSGEPQT FTLKFKRAED YPIDLYLMD LSYSMKDDLE
NVKSLGTDLM NEMRITSDF RIGFGSFVEK TVMPYISTTP AKLRNPCTSE QNCTTFFSYK NVLSLTNKGE VFNELVGKQR
ISGNLDSPEG GFDAMQVAV CGSLIGWRNV TRLLVFSTDA GFHFAGDGKL GGIVLPNDGQ CHLENMNYTM SHYYDPSIA
HLVQKLSENN IQTIFAVTEE FQPVYKELKN LIPKSAVGTI SANSSNVIQL IIDAYNSLSS EVILENGKLS EGVITISYKSY
CKNGVNGTGE NGRKCSNISI GDEVQFEISI TSNKCPKDS DSFKIRPLGF TEEVEVILQY ICECECQSEG IPESPKCHEG
NGTFECGACR CNEGRVGRHC ECSTDEVNSE DMDAYCRKEN SSEICSNNGE CVCGQCVRK RDNTNEIYSG KFCECDNFNC
DRSNGLICGG NGVCKRVCE CNPNYTGSA CDSLDTSTCE ASNGQICNGR GICECGVCKC TDPKFGQTC EMCQTCLGVC
AEHKECVQCR AFNKGEK KDT CTQECSYFNI TKVESRDKLP QPVQDPVSHK CKEKDVDCCW FYFTYSVNGN NEVMVHVVEN
PECPTGPDII PIVAGVVAGI VLIGLALLI WKLMIHHR REFAPFEKEK MNAKWDTGEN PIYKSAVTTV VNPKYEGK
```

Mass (mono): 88407.0 Identifier: gi|4504767 Database: d:/Xcalibur/database/nr.fasta  
 Protein Coverage: 99/798 = 12.4% by amino acid count, 11077.3/88407.0 = 12.5% by mass



Sort by:  Sequence  Position

Peptide	Position
<a href="#">DKLPQPVQDPVSHCK</a>	677 - 692
<a href="#">FCECDNFNCDR</a>	552 - 562
<a href="#">GEVFNELVGK</a>	229 - 238
<a href="#">IGFGSFVEK</a>	182 - 190
<a href="#">LSEGVITISYK</a>	389 - 398
<a href="#">SGEPQFTTLK</a>	125 - 134
<a href="#">SLGTDLMNEMR</a>	164 - 174
<a href="#">TVMPYISTTPAK</a>	191 - 202
<a href="#">WDTGENPIYK</a>	775 - 784


## Protein i.d. case study conclusions

- Protein confirmed as integrin beta-1
- All experiments were performed in a single nano-LC/MS/MS run using data-dependent scanning
- 9 different peptides from the protein were confirmed as database search hits
- Several oxidized Met peptides were observed (likely the result of the in-gel digest procedure)

# Opportunities for Automation

- Automated sample handling
  - Minimize sample losses through sample transfer and handling steps
  - Concentrate, desalt, remove contaminants on-line
  - Digest on-line (combine with data-dependent triple play for completely automated peptide mapping system)
  - Rank large-small molecule affinities on-line
- Data-manipulation (bioinformatics - a whole new area)
  - What to do with SEQUEST output
  - Automated in-tact protein analysis


# Schematic of Automated Sample Cleanup and Fraction Collection System




# Automated protein sample preconcentration/cleanup

50 pmoles of crude isolate in 300  $\mu$ L


11834 Da




# Automated protein sample cleanup system with on-line SDS detergent removal




# Mass spectra of 25 pmol myoglobin in 0.1% SDS no SDS removal



# Mass spectra of 25 pmol myoglobin in 0.1% SDS using automated SDS removal



# Automated Micro-scale On-line Digest/Ion Trap System




PerSeptive Biosystems  
Integral Workstation

## Digest Sequence

- draw sample into loop
- backflush thru PZT w/digest buffer
- flip INJ, wash PZT, desalt trap
- flip V2, gradient elute peptides
- flip V1, clean PZT

# Schematic of On-line Affinity LC/MS System


## “automated affinity applause meter”




### Affinity LC/MS sequence:

- draw sample into loop
- backflush, capture ligands on affinity column
- flip V2 (trap in line), flip INJ, elute ligands onto trap
- flip V1, wash trap with 0.1% TFA
- flip V2, elute/separate ligands
- detect by LC/MS<sup>n</sup>

# Affinity LC/Ion Trap/MS/MS of 4-Component Mixture using immobilized Thrombin



# Affinity LC/MS Binding Profile of ACE Inhibitors



## *In Vitro* Activity

SQ-25995 > Captopril > SQ-14304 > SQ-14224 > SQ14215 > SQ27521 > SQ26688  
2.9 nM      23 nM      435 nM      965 nM      5.7  $\mu$ M      565  $\mu$ M      2.4 mM

## Conclusions: Analytical Figures of Merit of LC/MS for Biomolecule Analysis

- Excellent Mass Accuracy
  - +/- 0.01% routine (1 Da in 10 kDa)
- Resolving Power
  - e.g., a 100 Da change can be detected in a 150 kDa antibody
- Rapid
  - minutes
- High Sensitivity
  - picomole - attomole depending on sample handling
- Automation capability
  - increased throughput
  - increased sensitivity via reduction of manual sample handling steps
- LC/MS<sup>N</sup> is a powerful tool for biomolecule structure analysis, - profiling, sequence, interaction

# Acknowledgments

- Bristol-Myers Squibb
  - Mark Sanders, Mike Nedved, Haiying Zhang, Subinay Ganguli
- Tufts University
  - Dr. Dan Jay

# Internet Resources for LC/MS and Bio-MS

- ThermoFinnigan
  - <http://www.thermofinnigan.com>
- Novatia (brand new but adding new content - tips on SEQUEST usage)
  - <http://www.enovatia.com>
- Base peak from Wiley (a good MS link site, commercial and academic)
  - <http://base-peak.wiley.com>
- ABRF (good source for biological apps, join the ABRF list server)
  - <http://www.abrf.org>
- Ion Source (good information and tutorials, links)
  - <http://ionsource.com>
- Prowl at Rockefeller University (good bioMS site, useful software - PAWS)
  - <http://prowl.rockefeller.edu>